Inhibrx Biosciences, Inc. (INBX) financials · rev $1.3M
Lician Pro · $19.99/mo or $149/yrCompare AAPL vs MSFT
Inhibrx Biosciences, Inc. (INBX) rev $1.3M.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $1.30M | $200.0K |
| Operating Income | -$135.0M | -$331.4M |
| Net Income | -$140.1M | $1.69B |
| EPS (Diluted) | -$9.04 | $112.62 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $146.5M | $180.8M |
| Current Assets | $132.8M | $160.4M |
| Cash & Equivalents | $124.2M | $152.6M |
| PP&E | $3.73M | $6.20M |
| Total Liabilities | $138.5M | $47.2M |
| Current Liabilities | $33.8M | $40.7M |
| Long-term Debt | $100.6M | N/A |
| Total Debt | $100.6M† | N/A |
| Shareholders' Equity | $7.99M | $133.6M |
| Retained Earnings | -$246.2M | -$106.1M |
† Total Debt: Derived from long-term debt only (no total or short-term debt stored).
| Line | FY2025 | FY2024 |
|---|---|---|
| Operating Cash Flow | -$129.8M | -$194.4M |
| CapEx | $31.0K | $2.60M |
| Investing Cash Flow | -$28.0K | -$2.60M |
| Financing Cash Flow | $101.4M | $71.7M |
| Net Change in Cash | -$28.4M | -$125.3M |
| Free Cash Flow | -$129.8M | -$197.0M |
FAQ
What is INBX P/E and revenue?
Inhibrx Biosciences, Inc. (INBX) rev $1.3M.
What is INBX revenue?
Inhibrx Biosciences, Inc. last cached revenue is $1.30M (FY2025).
Is INBX profitable?
Inhibrx Biosciences, Inc. last cached net income is -$140.1M (FY2025).
What are INBX total assets?
Inhibrx Biosciences, Inc. last cached total assets are $146.5M (FY2025).
What is INBX free cash flow?
Inhibrx Biosciences, Inc. last cached free cash flow is -$129.8M (FY2025).
Not investment advice. Cached statements, not a live tape.